MAGE-1 Antibody [SPM282]

Product Specifications

Background

Recognizes a protein of 42-46kDa, identified as MAGE-1. This mAb does not cross-react with MAGE-2, -3, -4, -6 -9, -10, -or -12 protein. Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL) . The MAGE family of genes codes an important group of antigens. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs) . Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy.

NCBI Gene ID

4100

Swiss Prot

P43355

Host

Mouse

Reactivity

Human, Rat, Dog

Immunogen

Full length human protein was used as the immunogen for this MAGE-1 antibody.

Clonality

Monoclonal

Clone

SPM282

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Cancer

Purification

Protein G affinity chromatography

Concentration

0.2 mg/mL

Buffer

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.

Fragment

IgG1, kappa

Applications Notes

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes. 2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.